<p>The biological determinants of sensitivity and resistance to immune checkpoint inhibitors are not completely understood. To elucidate the role of intratumoral T-cells and its association with the tumor genomic landscape, we perform paired whole exome DNA sequencing and multiplexed quantitative immunofluorescence (QIF) in pre-treatment samples from non-small cell lung carcinoma patients treated with PD-1 axis blockers. QIF was used to simultaneously measure the level of CD3+ tumor infiltrating lymphocytes (TILs), in situ T-cell proliferation (Ki-67 in CD3) and effector capacity (Granzyme-B in CD3). Whole exome sequencing reported in the number/type of mutations and predicted class I and class II mutant neoantigens.</p>

Dormant TILs and Sensitivity to Immune Checkpoint Blockers in Lung Cancer

Neoplasms study with SNP Genotypes (NGS), WXS data on dbGaP (49 participants)

Dormant TILs and Sensitivity to Immune Checkpoint Blockers in Lung Cancer

Description

Applying For Access

Summary